Key facts
- It has raised $30.2M across 2 recorded rounds; the latest was Seed Round ($3.9M) in Jul 2022.
- Spectrum Antimicrobials has filed 7 Form Ds with the SEC since 2020, most recently Oct 2024 ($13.4M sold to 108 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Spectrum Antimicrobials
Funding rounds
2 roundsAbout Spectrum Antimicrobials
Developer of infection treatment therapeutics intended to reshape the standard of care through products that focus on controlling, preventing, and treating infectious diseases. The company focuses on fostering commercialized technologies and improving the future of global health by delivering assets to critically serve areas of need, enabling caregivers to combat viral, bacterial, fungal, and mold-caused infections in wounds without causing antibiotic resistance.
- Sector
- Healthcare
- HQ
- Petaluma, CA, United States
- Founded
- 2016
- Employees
- 11
- Website
- spectrumantimicrobials.com/
- Ownership
- Privately Held (backing)
Spectrum Antimicrobials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spectrum Antimicrobials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spectrum Antimicrobials in its N-PORT filings yet. We sweep new filings monthly.